Product Description
a new investigational anti-inflammatory agent
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: N/A
Route of Administration: Topical,Nasal
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Evolutec Group
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Rhinitis, Allergic, Seasonal|Cataract|Inflammation|Capsule Opacification
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
EV-71-004 | P2 |
Unknown status |
Rhinitis, Allergic, Seasonal |
None |
|
EVOL-PRO-06-024 | P2 |
Unknown status |
Cataract|Inflammation|Capsule Opacification |
None |